search
Back to results

Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants (OTBB2)

Primary Purpose

Prader Willi Syndrome

Status
Completed
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
oxytocin
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prader Willi Syndrome focused on measuring Prader Willi

Eligibility Criteria

1 Month - 5 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Infants with PWS genetically confirmed
  • Aged less than 5 months

Exclusion Criteria:

  • Infants presenting hepatic insufficiency
  • Infants presenting renal insufficiency
  • Infants with abnormal ECG

Sites / Locations

  • Centre de réfrence Prader-Willi, Hospital of infants

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

first arm

second arm

third arm

Arm Description

4IU of oxytocin every other day

4 IU of oxytocin daily

4 IU of oxytocin twice daily

Outcomes

Primary Outcome Measures

Occurence of adverse event
Occurrence of adverse event, description and quantification of their severity, imputability to repeated intranasal administration of OT (4IU every other day, 4 IU daily, 4IU twice daily) during the 7 days following the first administration.

Secondary Outcome Measures

Efficacy, pathophysiological study
Preliminary study of efficacy on suckling and swallowing and quantity of milk intake/day infant-mother interactions before during and after feeding weight gain and growth Pathophysiological study of cerebral metabolism (fMRI bold) plasma levels of ghrelin and other peptides involved in feeding behaviour or energy metabolism

Full Information

First Posted
July 22, 2014
Last Updated
July 26, 2021
Sponsor
University Hospital, Toulouse
search

1. Study Identification

Unique Protocol Identification Number
NCT02205034
Brief Title
Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Acronym
OTBB2
Official Title
Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Prader-Willi syndrome (PWS) includes severe neonatal hypotonia with impaired suckling leading to failure to thrive in the most severe cases, subsequently followed by an early onset of morbid obesity with hyperphagia and deficit of satiety, combined with other endocrine dysfunction probably due to hypothalamic dysfunction. The pathophysiological mechanism of the occurrence of the 2 main nutritional phases of PWS is unknown. Swaab reported a deficit in the oxytocin (OT)-producing neurons of the paraventricular nucleus in the brain of these patients. In addition of its well-known anorexigenic effect, OT is involved in establishing and maintaining social codes. Moreover in a PWS mouse model generated from a MAGEL2 KO gene a single OT injection at 5 hr of life prevent the early death observed in 50 % of the new born mice by recovering normal suckling. Interestingly this effect is no longer observed if OT injection takes place later. Our hypothesis is that early administration of OT in babies with PWS may improve suckling and possibly infant-mother interactions. In our recent study (manuscript in preparation), we have shown that a single intranasal administration of OT is well tolerated. This escalating dose study is designed to evaluate the tolerance of repeated intranasal administration of OT in 3 steps (4IU every other day, 4 IU daily, 4IU twice daily) in babies younger than 5 months with PWS.
Detailed Description
Prader-Willi syndrome (PWS) is a rare, complex multisystem genetic disorder arising from the lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13. The syndrome includes severe neonatal hypotonia with impaired suckling leading to failure to thrive in the most severe cases, subsequently followed by an early onset of morbid obesity with hyperphagia and deficit of satiety, combined with other endocrine dysfunction probably due to hypothalamic dysfunction. The pathophysiological mechanism of the occurrence of the 2 main nutritional phases of PWS is unknown. Swaab reported a deficit in the oxytocin (OT)-producing neurons of the paraventricular nucleus in the brain of these patients. In addition of its well-known anorexigenic effect, OT is involved in establishing and maintaining social codes. Moreover in a PWS mouse model generated from a MAGEL2 KO gene a single OT injection at 5 hr of life prevent the early death observed in 50 % of the new born mice by recovering normal suckling. Interestingly this effect is no longer observed if OT injection takes place later. Our hypothesis is that early administration of OT in babies with PWS may improve suckling and possibly infant-mother interactions. In our recent study (manuscript in preparation), we have shown that a single intranasal administration of OT is well tolerated. This escalating dose study is designed to evaluate the tolerance of repeated intranasal administration of OT in 3 steps (4IU every other day, 4 IU daily, 4IU twice daily) in babies younger than 5 months with PWS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prader Willi Syndrome
Keywords
Prader Willi

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
first arm
Arm Type
Active Comparator
Arm Description
4IU of oxytocin every other day
Arm Title
second arm
Arm Type
Active Comparator
Arm Description
4 IU of oxytocin daily
Arm Title
third arm
Arm Type
Active Comparator
Arm Description
4 IU of oxytocin twice daily
Intervention Type
Drug
Intervention Name(s)
oxytocin
Other Intervention Name(s)
Oxytocin (Syntocinon)
Intervention Description
Intranasal administration
Primary Outcome Measure Information:
Title
Occurence of adverse event
Description
Occurrence of adverse event, description and quantification of their severity, imputability to repeated intranasal administration of OT (4IU every other day, 4 IU daily, 4IU twice daily) during the 7 days following the first administration.
Time Frame
up to day 8 (Visit 8)
Secondary Outcome Measure Information:
Title
Efficacy, pathophysiological study
Description
Preliminary study of efficacy on suckling and swallowing and quantity of milk intake/day infant-mother interactions before during and after feeding weight gain and growth Pathophysiological study of cerebral metabolism (fMRI bold) plasma levels of ghrelin and other peptides involved in feeding behaviour or energy metabolism
Time Frame
Up to day 8
Other Pre-specified Outcome Measures:
Title
Pharmacokinetic study
Description
Pharmacokinetic study : measurement of circulating oxytocin levels before administration and every 48hrs.
Time Frame
On day 2, 3, 4, 5, 6, 7, 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
5 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infants with PWS genetically confirmed Aged less than 5 months Exclusion Criteria: Infants presenting hepatic insufficiency Infants presenting renal insufficiency Infants with abnormal ECG
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maïthé TAUBER
Organizational Affiliation
Endocrinologie pédiatrique, Hospital of Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre de réfrence Prader-Willi, Hospital of infants
City
Toulouse
ZIP/Postal Code
31059
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
28100688
Citation
Tauber M, Boulanouar K, Diene G, Cabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Pourrinet J, Cessans C, Viaux-Sauvelon S, Bascoul C, Guedeney A, Delhanty P, Geenen V, Martens H, Muscatelli F, Cohen D, Consoli A, Payoux P, Arnaud C, Salles JP. The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome. Pediatrics. 2017 Feb;139(2):e20162976. doi: 10.1542/peds.2016-2976.
Results Reference
result
PubMed Identifier
33232306
Citation
Borie AM, Dromard Y, Guillon G, Olma A, Manning M, Muscatelli F, Desarmenien MG, Jeanneteau F. Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model. J Clin Invest. 2021 Jan 19;131(2):e144450. doi: 10.1172/JCI144450.
Results Reference
derived

Learn more about this trial

Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants

We'll reach out to this number within 24 hrs